(Length of Discussion: 4 min)

Dr. Thomas Keane reviews the Subgroup Analysis of Progression-free Survival and Objective Response Rate in the Alliance AO31203 CABOSUN trial for Advanced Renal Carcinoma presentation by Dr. Daniel George at the ASCO GU 2018 meeting.  Cabozantinib, a small molecule designed to target the MET and ALK pathways in addition to VEGFR2 pathway has been shown to be superior to everolimus in the second-line setting and most recently superior to sunitinib for the treatment of intermediate and poor risk patients with treatment naïve metastatic RCC.

Dr. Thomas Keane provides thorough detail on the the sub group progression-free survival and objective response rates analysis.  In summary, cabozantinib showed improved progression-free survival  and objective response rates compared to sunitinib as an initial targeted therapy for patients with treatment naïve mRCC. The results remained consistent within all the subgroups defined by baseline characteristics. MET positivity has the potential to become a predictive biomarker for patients considering treatment with cabozantinib. 


Read More Related Content:

Subgroup Analysis of Progression-free Survival and Objective Response Rate in the Alliance AO31203 CABOSUN trial - Advanced Renal Cell Carcinoma

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Complete ASCO GU 2018 Meeting Coverage

Biography:

Thomas E. Keane, MBBCh, FRCSI, FACS